Pathological Changes in APP/PS-1 Transgenic Mouse Models of Alzheimer's Disease Treated with Ganoderma Lucidum Preparation.

Abstract

Objective To explore the efficacy of ganoderma lucidum preparation(Ling Zhi) in treating APP/PS-1 transgenic mouse models of Alzheimer's disease(AD).Methods APP/PS-1 transgenic mice of 4 months were randomly divided into model group,ganoderma lucidum treatment groups,including high [2250 mg/(kg·d)] and middle [750 mg/(kg·d)] dose groups,i.e.LZ-H and LZ-M groups,and the positive control group(treated with donepezil hydrochloride [2 mg/(kg·d)]).In addition,C57BL/6J wild mice were selected as normal group.The animals were administered for 4 months.Histopathological examinations including hematoxylin-eosin(HE) staining,immunohistochemistry,special staining,and electron microscopy were applied,and then the pathological morphology and structures in different groups were compared. Results The senile plaques and neurofibrillar tangles in the cerebrum and cerebellum were dissolved or disappeared in LZ-H and LZ-M groups.Decrease of amyloid angiopathy was found in LZ-H and LZ-M groups.The immature neurons appeared more in hippocampus and dentate nucleus of LZ-H and LZ-M groups than those in AD model and donepezil hydrochloride groups(hippcampus:F=1.738,P=0.016;dentate nucleus:F=1.924,P=0.026),and these immature neurons differentiated to be neurons.More Purkinje cells loss occurred in AD model mice than that in LZ-H and LZ-M groups(F=9.46,P=0.007;F=9.46,P=0.010).The LZ-H and LZ-M groups had more new neuron stem cells grown up in cerebellum.Electromicroscopic examination showed the hippocampal neurons in LZ-H and LZ-M group were integrated,the nuclear membrane was intact,and the mitochondria in the cytoplasm,endoplasmic reticulum,Golgi bodies,microtubules,and synapses were also complete.The microglial cell showed no abnormality.No toxicity appeared in the pathological specimens of mice treated with ganoderma lucidum preparation.Conclusion The ganoderma lucidum preparation can dissolve and decline or dismiss the senile plaques and neurofibrillar tangles in the brain of AD mice and also reduce the amyloid angiopathy.

• Authors: Chuan Qin, Shan-Qiu Wu, Bao-Sheng Chen, Xiao-Xian Wu, Kun-Yao Qu, Jun-Min Liu, Gui-Fang Zhang, Yan-Feng Xu, Shunli Shu, Lihua Sun, Yan-Yong Li, Hua Zhu, Lan Huang, Chun-Mei Ma, Yu-Huan Xu, Yun-Lin Han, Yao-Zeng Lu
• Journal: Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae (Zhongguo Yi Xue Ke Xue Yuan Xue Bao) Vol. 39 Issue 4 Pg. 552-561 (Aug 20 2017) ISSN: 1000-503X [Print] China
• Vernacular Title: 灵芝制剂治疗APP/PS-1阿尔茨海默病转基因小鼠模型的病理学改变.
• PMID: 28877835 (Publication Type: Journal Article)

Chemical References

• Amyloid beta-Protein Precursor
• Biological Products

Topics

• Alzheimer Disease (drug therapy)
• Amyloid beta-Protein Precursor
• Animals
• Biological Products (therapeutic use)
• Disease Models, Animal
• Hippocampus (cytology)
• Mice
• Mice, Inbred C57BL
• Mice, Transgenic
• Random Allocation
• Reishi (chemistry)